This report delineates the clinical, genetic, and multimodal imaging characteristics of Benign Familial Fleck Retina (BFFR) and Dominant Drusen—also termed Doyne Honeycomb Retinal Dystrophy (DHRD) or Malattia Leventinese (MLVT). While both present with a “flecked retina” phenotype, their molecular etiologies and longitudinal prognoses necessitate careful differentiation.

The primary clinical differentiator is the status of the posterior pole. Benign Familial Fleck Retina (BEFR) is defined by absolute macular sparing, maintaining normal foveal architecture.

In Dominant Drusen, the macula is the primary site of disease, where confluent drusenoid deposits eventually lead to pigment proliferation or atrophy.

1. Genetic Basis and Pathophysiology

The molecular basis of these conditions involves distinct protein dysfunctions that impact Retinal Pigment Epithelium (RPE) homeostasis. Practitioners should note that PLA2G5 variants are frequently classified as variants of unknown significance (VUS) and require meticulous clinical correlation.

——————————————————————————–

2. Clinical Presentation and Symptomatology

While traditionally considered a stationary and asymptomatic condition, recent evidence (Constable, 2023) indicates that late-onset variants of BFFR may present with functional deficits.

——————————————————————————–

3. Funduscopic Morphology and Retinal Distribution

Morphological patterns remain the cornerstone of bedside differentiation.

• BFFR Distribution: Characterized by widespread, discrete yellow-white sub-retinal flecks. A hallmark is the sparing of the macula, optic disc, and peripapillary area for approximately one disc diameter—except inferiorly, where lesions may involve the margin of the optic disc (Isaacs et al., 1996). Lesions exhibit a “marbelised” or “breadcrumb” appearance, increasing in size toward the periphery into confluent amoeboid or linear shapes.
• Dominant Drusen (DHRD/MLVT) Distribution: Displays a characteristic “Honeycomb” or “Radial” pattern. Small-to-medium drusen are centered on the macula and extend along the vascular arcades. Unlike BFFR, there is explicit involvement of the peripapillary region, particularly nasal to the disc.
• Comparison of the Macula: The primary clinical differentiator is the status of the posterior pole. BFFR is defined by absolute macular sparing, maintaining normal foveal architecture. In DHRD, the macula is the primary site of disease, where confluent drusenoid deposits eventually lead to pigment proliferation or atrophy.

“Benign Familial Fleck Retina” by Jitendra Kumar Sahoo, M Optom, Chitaranjan Mishra, DNB, MRCSEd, Rubina Bhoi, VT, Shiva Prasad Sahoo, MS (Trilochan Netralaya, Betty White Ashram, Jamadarpali, Sambalpur, Odisha-768200, India). Equipment: Canon CX-1 Hybrid Digital Mydriatic/Non-Mydriatic Retinal Camera (Canon Medical Systems USA, Inc.). Published in the September 2025 issue of Ophthalmology Retina.

A hallmark is the sparing of the macula, optic disc, and peripapillary area for approximately one disc diameter—except inferiorly, where lesions may involve the margin of the optic disc.

Dominant Drusen- One patient (25 years old) with a de novo heterozygote R345W mutation in the EFEMP1 gene. (a, b) Fundus color of the right eye (RE) and the left eye (LE): large, confluent drusen at posterior pole and nasal of the optic disc, small radial drusen. One juxtapapillary drusen RE, otherwise sparing (normal retina) around the optic discs. Visual acuity: 0.5 corrected, both eyes. (c–e) Fundus autofluorescence (FAF) images of RE and LE: hyperautofluorescence of drusen, area of hypofluorescence at the fovea in both eyes. (d–f) Spectral-domain optical coherence tomography of RE, LE: diffuse deposition of hyperreflective material underneath the retinal pigment epithelium (RPE) – diffuse, dome-shaped elevation of the RPE (large drusen).

——————————————————————————–

4. Multimodal Imaging Characteristics

• Optical Coherence Tomography (OCT):
  • BFFR: Shows localized sub-retinal elevations at the RPE-Bruch’s membrane interface. Larger flecks may correspond to focal disruption of the ellipsoid zone (EZ).
  • DHRD: Reveals drusenoid deposits between the RPE and Bruch’s membrane (focal dome-shaped or saw-tooth). Advanced stages demonstrate diffuse EZ loss and outer retinal atrophy.
• Fundus Autofluorescence (FAF):
  • BFFR: Flecks demonstrate marked hyperautofluorescence (consistent with lipofuscin). Atypical cases may show arcuate crescents of hypofluorescence indicating RPE loss.
  • DHRD: Drusen display variable (hyper/hypo) autofluorescence; areas of GA appear markedly hypo-autofluorescent.
• Fluorescein Angiography (FA):
  • BFFR: Often “silent” or unhelpful; irregular hyperfluorescence may be seen that does not strictly correspond to clinical flecks.
  • DHRD: Large drusen exhibit late hyperfluorescence. Essential for monitoring CNVM leakage.
• Indocyanine Green Angiography (ICG):
  • DHRD (Differentiating Pattern): Large central drusen initially appear hypofluorescent, becoming hyperfluorescent with a hypofluorescent halo in late phases. Small radial drusen are hyperfluorescent in early phases and show decreased fluorescence in late phases.

——————————————————————————–

5. Visual Function and Electrophysiology

• Visual Acuity: Stable 20/20 in typical BFFR. In advanced DHRD (7th–8th decades), acuity often falls below 20/200 due to GA or CNVM.
• Electroretinography (ERG/EOG):
  • BFFR: Typically normal full-field ERG and EOG. Atypical late-onset variants may demonstrate reduced dark-adapted (DA) a-wave amplitudes and delayed b-wave recovery (Constable 2023).
  • DHRD: Full-field ERG is often normal, but the pattern ERG (PERG) is frequently abnormal, reflecting macular dysfunction. EOG light-rise abnormalities may be present.

——————————————————————————–

6. Clinical Prognosis and Management

• BFFR Prognosis: Historically considered benign and stationary; however, clinicians should monitor for late-onset functional deterioration in specific genotypes.
• Dominant Drusen Prognosis: Guarded and progressive; carries a high risk of legal blindness in late stages due to GA or CNVM.
• Management Recommendations:
  • Observation & Monitoring: Standard for BFFR. Use Ishihara and Farnsworth D-15 color tests alongside OCT to monitor for functional and structural changes.
  • Anti-VEGF Therapy: Gold standard for DHRD-related CNVM (e.g., Bevacizumab) to resolve fluid and preserve vision.
  • Laser Therapy: Consider the 2RT nanosecond laser for DHRD, which has demonstrated potential for clearing drusen and improving retinal sensitivity/multifocal ERG.
  • Genetic Counseling: Essential for both. Sibling screening for recessive BFFR; vertical screening for dominant DHRD.

——————————————————————————–

7. Differential Diagnosis Summary

Clinicians should utilize the following checklist to distinguish these syndromes:

• [ ] Macular Sparing? If present, strongly suspect BFFR.
• [ ] Involvement Nasal to the Disc? Hallmark of Dominant Drusen.
• [ ] Nyctalopia Present? If yes, consider Dominant Drusen or Atypical BFFR (requires extended dark-adapted ERG).
• [ ] Radial/Honeycomb Pattern? Pathognomonic for Dominant Drusen.
• [ ] Amoeboid Peripheral Flecks? Suggestive of BFFR.
• [ ] Inferior Peripapillary Involvement? Possible in BFFR despite general peripapillary sparing.
• [ ] Family History? Autosomal Dominant suggests DHRD; Recessive or sporadic suggests BFFR.